The POG project, led by Drs. Marco Marra and Janessa Laskin, integrates new technologies with whole genome and transcriptome analysis (WGTA) to advance precision cancer medicine. However, WGTA faces challenges such as low tumor material recovery from biopsies, low tumor content samples, and the cellular heterogeneity of tumors, which can hinder the identification of therapeutic targets. To overcome these limitations, we are assembling a cohort of POG samples for single-nucleus multi-omics analysis alongside standard WGTA, with an initial focus on low tumor content non-small cell lung cancers and cases with longitudinal biopsies. This approach will determine whether single-nucleus multi-omics expands the pool of suitable patient materials and improves eligibility for precision cancer treatments.